Here's Where Wall Street Analysts See Eli Lilly's Share Price Going

Wall Street analysts see 11% upside for LLY, setting an average price target of $1,325 despite the stock's underperformance versus the broader market in 2026. Of 30 analysts covering the name, 25 rate it a buy.

The bullish case hinges on the GLP-1 market, projected to reach $190 billion by 2045, and Eli Lilly's patent protection extending through the late 2030s. LLY currently trades at 40x earnings following a strong five-year run, though 2026 year-to-date performance has lagged benchmarks.

NVO remains a competitive threat in the weight-loss and diabetes space, but analysts maintain a modestly positive stance on Eli Lilly's positioning within the rapidly expanding GLP-1 category.